Reported about 20 hours ago
Exact Sciences Corporation (NASDAQ:EXAS) has expanded the validation of its Oncodetect™ test for monitoring colorectal cancer recurrence, presenting new data from the Beta-CORRECT study at ASCO 2025. This research shows that patients with positive ctDNA results exhibit significantly higher recurrence risks. Additionally, the company plans to launch a next-generation test in 2026 using MAESTRO technology to enhance detection capabilities, marking a significant advance in molecular residual disease identification.
Source: YAHOO